Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04166604 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy

Study acronym: LONGBOARD
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Nov 2024 to Nov 2025v10
  2. Trial status: Recruiting to Active, Not Recruitingv9 Show 4 more changesShow less
    • Enrollment target: estimated 250 to confirmed 176
    • Primary completion date changed from estimate of Dec 2023 to Nov 10, 2023
    • Study completion date: Jun 15, 2024 to Nov 2024
    • Site details revised at 22 of 22 sites
  3. Primary endpoint revised
    • Primary completion date: Jul 15, 2023 to Dec 2023
    • Secondary endpoints: 10 to 7
    v8
  4. Primary completion date: Nov 15, 2021 to Jul 15, 2023
    • Study completion date: Jun 15, 2022 to Jun 15, 2024
    v7
  5. 2 versions Re-verified since Nov 17, 2020, no change to tracked fieldsv5-v6
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 15, 2020 to May 20, 2020
    • Site details revised at 22 of 22 sites
    v4
  2. Start date: Feb 15, 2020 to May 15, 2020v3
  3. Start date: Dec 10, 2019 to Feb 15, 2020v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Prospective cohort of patients treated with trifluridine/tipiracil, maximal sample size 250 patients. It is expected, that 89 patients will experience a grade 3-4 neutropenia and will be included in the phase II.
Trial Details
NCT Number NCT04166604
Lead Sponsor GERCOR - Multidisciplinary Oncology Cooperative Group
Conditions
(from sponsor)		 Metastatic Colorectal Cancer
Related terms Colorectal Neoplasms, Neutropenia
Enrollment 176 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov